Reply: Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?

Ahmed Tawakol; Hamed Emami; Michael Farkouh; Zahi A. Fayad; Kenneth Fifer; James H.F. Rudd; Sharath Subramanian; Thomas Van Dyke

doi:10.1016/j.jacc.2014.03.038

Reply: Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?

Ahmed Tawakol, Hamed Emami, Michael Farkouh, Zahi A. Fayad, Kenneth Fifer, James H.F. Rudd, Sharath Subramanian, Thomas Van Dyke

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	2881-2882
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	63
Issue number	25 PART A
DOIs	https://doi.org/10.1016/j.jacc.2014.03.038
State	Published - 1 Jul 2014

Access to Document

10.1016/j.jacc.2014.03.038

Cite this

@article{410da7ff2914427ebd29ca32592cac58,

title = "Reply: Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?",

author = "Ahmed Tawakol and Hamed Emami and Michael Farkouh and Fayad, {Zahi A.} and Kenneth Fifer and Rudd, {James H.F.} and Sharath Subramanian and {Van Dyke}, Thomas",

note = "Funding Information: Please note: Merck & Co., Inc. provided funding for the original study. Drs. Tawakol and Fayad received consulting fees and their institutions received grants from Roche and Merck Sharp & Dohme Corp. , a subsidiary of Merck & Co., Inc. Dr. Farkouh's institution received grants from Merck Sharp & Dohme Corp . Dr. Rudd is supported by the NIHR Cambridge Biomedical Research Centre . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2014",

month = jul,

day = "1",

doi = "10.1016/j.jacc.2014.03.038",

language = "English",

volume = "63",

pages = "2881--2882",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "25 PART A",

}

TY - JOUR

T1 - Reply

T2 - Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?

AU - Tawakol, Ahmed

AU - Emami, Hamed

AU - Farkouh, Michael

AU - Fayad, Zahi A.

AU - Fifer, Kenneth

AU - Rudd, James H.F.

AU - Subramanian, Sharath

AU - Van Dyke, Thomas

N1 - Funding Information: Please note: Merck & Co., Inc. provided funding for the original study. Drs. Tawakol and Fayad received consulting fees and their institutions received grants from Roche and Merck Sharp & Dohme Corp. , a subsidiary of Merck & Co., Inc. Dr. Farkouh's institution received grants from Merck Sharp & Dohme Corp . Dr. Rudd is supported by the NIHR Cambridge Biomedical Research Centre . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2014/7/1

Y1 - 2014/7/1

UR - http://www.scopus.com/inward/record.url?scp=84903218660&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2014.03.038

DO - 10.1016/j.jacc.2014.03.038

M3 - Letter

C2 - 24794123

AN - SCOPUS:84903218660

SN - 0735-1097

VL - 63

SP - 2881

EP - 2882

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 25 PART A

ER -